BNTX vs INSM
BioNTech SE and Insmed Incorporated, both Healthcare
BioNTech SE is the larger company at $23B against $21B. Over the past year INSM returned +14% against +1.1% for BNTX. Ryufin's sector-relative Smart Score puts BNTX ahead, 5/10 against 2/10.
| Figure | BNTX | INSM |
|---|---|---|
| Last close | $113 | $124 |
| Market cap | $23B | $21B |
| 1-year return | +1.1% | +14% |
| 5-year return | -66% | +415% |
| Ryufin Smart Scoresector-relative, 1–10 | 5/10 | 2/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
BioNTech SE
Insmed Incorporated
Revenue of $425M in Q2 2026, net income null. Its largest reported line is United States, 60% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.